| Theme | Therapeutic strategy for ulcerative colitis ; from standard to up-to-date | |
|---|---|---|
| Title | Effects of anti-TNFα antibodies for patients with refractory ulcerative colitis | |
| Publish Date | 2011/05 | |
| Author | Satoshi Motoya | IBD Center, Sapporo Kosei General Hospital |
| Author | Masaki Yamashita | IBD Center, Sapporo Kosei General Hospital |
| Author | Hiroki Tanaka | IBD Center, Sapporo Kosei General Hospital |
| Author | Akimichi Imamura | IBD Center, Sapporo Kosei General Hospital |
| [ Summary ] | Infliximab, an anti-tumor necrosis factor alpha monoclonal antibody, is effective in inducing and sustaining clinical remission for patients who are moderately to severely steroid-refractory, steroid-dependent, or where immune-modulators have failed for ulcerative colitis (UC) treatment. However, while the efficacy of infliximab for patients with UC has been demonstrate it is not substantial for patients with Crohn's disease. It is also unknown if infliximab contributes to long-term remission or what are the predictors of positive outcomes with its use. Scheduled maintenance with infliximab may substantially improve QOL for patients with UC and may avoid colectomies, when they have a primary positive response to infliximab. |
|